PRECIGEN, INC. Long-Term Debt, Maturity, Remainder of Fiscal Year
PRECIGEN, INC. (PGEN) had Long-Term Debt, Maturity, Remainder of Fiscal Year of $0 as of 2025-09-30, per its 10-Q filed 2025-11-13.
Financial Statements › Notes › Commitment and Contingencies
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear · last filed 2025-11-13
- 2025-09-30: Long-Term Debt, Maturity, Remainder of Fiscal Year $0.00.
- 2022-06-30: Long-Term Debt, Maturity, Remainder of Fiscal Year $0.00.
- 2022-03-31: Long-Term Debt, Maturity, Remainder of Fiscal Year $265.00K.
- 2021-09-30: Long-Term Debt, Maturity, Remainder of Fiscal Year $90.00K.
| Period end | Long-Term Debt, Maturity, Remainder of Fiscal Year |
|---|---|
| 2025-09-30 | $0.00 10-Q · filed 2025-11-13 |
| 2022-06-30 | $0.00 10-Q · filed 2022-08-08 |
| 2022-03-31 | $265.00K 10-Q · filed 2022-05-09 |
| 2021-09-30 | $90.00K 10-Q · filed 2021-11-08 |
| 2021-06-30 | $181.00K 10-Q · filed 2021-08-09 |
| 2021-03-31 | $272.00K 10-Q · filed 2021-05-10 |
| 2020-09-30 | $25.17M 10-Q · filed 2020-11-09 |
| 2020-06-30 | $56.95M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $31.80M 10-Q · filed 2020-05-11 |
| 2019-09-30 | $127.00K 10-Q · filed 2019-11-12 |
| 2019-06-30 | $241.00K 10-Q · filed 2019-08-09 |
| 2019-03-31 | $418.00K 10-Q · filed 2019-05-09 |
| 2018-09-30 | $210.00K 10-Q · filed 2018-11-08 |
| 2018-06-30 | $283.00K 10-Q · filed 2018-08-13 |
| 2018-03-31 | $398.00K 10-Q/A · filed 2018-08-13 |
| 2017-09-30 | $107.00K 10-Q · filed 2017-11-09 |
| 2017-06-30 | $213.00K 10-Q · filed 2017-08-09 |
| 2017-03-31 | $291.00K 10-Q · filed 2017-05-10 |
| 2016-09-30 | $168.00K 10-Q · filed 2016-11-09 |
| 2016-06-30 | $298.00K 10-Q · filed 2016-08-09 |
| 2016-03-31 | $798.00K 10-Q · filed 2016-05-10 |
| 2015-09-30 | $506.00K 10-Q · filed 2015-11-09 |
| 2015-06-30 | $809.00K 10-Q · filed 2015-08-10 |
| 2015-03-31 | $1.12M 10-Q · filed 2015-05-11 |
| 2014-09-30 | $309.00K 10-Q · filed 2014-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |